Search
Displaying 241–250 of 526 for “Retinitis pigmentosa”
-
Beacon Stories
Michael was matched with his first guide dog, Geo, a yellow Labrador retriever, in March 2020, two years after he applied with Guiding Eyes for the Blind. Michael and Geo now have a relationship unlike any other.
-
MeiraGTx and Janssen Recruiting for Phase 3 XLRP Gene Therapy Clinical Trial
Research NewsVisit www.LUMEOSstudy.com for more information about trial
-
Telling His Story of Resilience
Beacon StoriesChad has been working in the corporate world for the last 20 years. But after becoming the first blind executive to graduate from the Harvard Business School leadership program, he realized his purpose in life is to help others by sharing the lessons he learned while losing his eyesight. He can now add published author to his repertoire with his new book, Blind Ambition.
-
Optogenetics: Hope for Vision Restoration for Advanced Retinal Diseases
Research NewsEarly, encouraging results from two human studies — trials launched by Bionic Sight and GenSight — are putting optogenetic therapies in the spotlight for patients with advanced vision loss from retinal conditions.
-
Nanoscope Therapeutics Launches Phase 2b Clinical Trial for Optogenetic Therapy
Research NewsWhile the trial is for people with RP, the company hopes it will also benefit people with other retinal degenerative diseases
-
Investigators Report Partial Vision Restoration for One Patient in Optogenetic Therapy Trial
Research NewsThe gene-agnostic approach is designed to restore some vision to people with advanced vision loss
-
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
Research NewsMore details from the clinical trial will be reported at a later date
-
AGTC Continues to Report Encouraging Data from its Phase 1/2 XLRP Gene Therapy Clinical Trial
Research NewsThe company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy
-
Research News
Precise and Sensitive Outcome Measures are Essential for Getting Vision Treatments through Clinical Trials
-
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Research NewsGene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
.png)
